Immix Biopharma (NASDAQ:IMMX) Issues Quarterly Earnings Results

Immix Biopharma (NASDAQ:IMMX) announced its quarterly earnings results on Monday. The company reported ($0.15) earnings per share (EPS) for the quarter, topping the consensus estimate of ($0.21) by $0.06, Zacks reports.

Immix Biopharma Trading Up 2.7 %

Shares of Immix Biopharma stock traded up $0.05 during trading hours on Wednesday, reaching $1.91. 55,361 shares of the company’s stock were exchanged, compared to its average volume of 205,516. The company has a 50 day moving average of $2.10 and a two-hundred day moving average of $2.53. The stock has a market cap of $50.45 million, a P/E ratio of -2.01 and a beta of 0.17. Immix Biopharma has a fifty-two week low of $1.55 and a fifty-two week high of $7.75.

Wall Street Analysts Forecast Growth

Separately, HC Wainwright restated a “buy” rating and set a $7.00 price objective on shares of Immix Biopharma in a report on Friday, July 26th.

Immix Biopharma Company Profile

Immix Biopharma, Inc, a clinical-stage biopharmaceutical company, engages in developing tissue-specific therapeutics in oncology and inflammation in the United States and Australia. The company is developing IMX-110 that is in Phase 1b/2a clinical trials for the treatment of soft tissue sarcoma and solid tumors; IMX-111, a tissue-specific biologic for the treatment of colorectal cancers; and IMX-120, a tissue-specific biologic for the treatment of ulcerative colitis and severe Crohn's disease.